Consuela A. Albright: Clinical Advocacy in Sickle Cell Disease
Consuela A. Albright, Nurse Practitioner at Cleveland Clinic, shared a post on LinkedIn:
“Advocacy isn’t only the work of patient organizations, it’s also the responsibility of the clinical and research community.
The American Society of Hematology (ASH) is the world’s largest professional society for blood disorder specialists, and sickle cell disease has long been a core focus of its advocacy arm.
ASH advocates for sustained NIH and NHLBI research funding, supports policies that expand access to emerging treatments and curative therapies, and works to build a hematology workforce that reflects the communities most affected by SCD.
As a clinician, I feel this aspect of advocacy most directly: the responsibility to translate bedside experience into policy input and to ensure the people setting research priorities hear from those providing day to day care.
Advocacy from the clinical side doesn’t replace patient led advocacy it should amplify it.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 15:00Brandon Buck: Human Cell-Free DNA as a Diagnostic Tool for Aging and Rare Blood Disorders
-
Sep 5, 2026, 14:57Archil Jaliashvili: What if Normal Hb and SpO₂ Still Do not Mean Adequate Tissue Oxygenation?
-
Sep 5, 2026, 14:52Evaluating Inhibitor Risk Following Factor Product Switches – Results from ATHN 2
-
Sep 5, 2026, 14:50Sandrine Oziel-Taieb: Hematological Toxicity Management During Lu-Dotatate
-
Sep 5, 2026, 14:43Nandini Pethe: How Digital Logs Help Recognize Pediatric von Willebrand Disease
-
Sep 5, 2026, 14:36Aremu David: Solving Tic-Tac-Toe in 7ms: How I Built Nine
-
Sep 5, 2026, 13:05Sheharyar Raza: Threshold-Based Transfusion in Sickle Cell Disease
-
Sep 5, 2026, 12:34Stijn Wigerinck: A Practical Roadmap for Eosinophilia and Hypereosinophilia
-
Sep 5, 2026, 11:51Alejandro González Veliz: Why Secondary Prevention Matters After PCI